Español 
Deutsch 
Français 
MSCI World Index (MSC)
NASDAQ Composite (NASDAQ)
FTSE China A50 Index (FGI)
STOXX Europe 600 (SIX)
Nikkei 300 (OSA)
NIFTY 50 (NSE)
DAX Performance Index (XETRA)
FTSE 100 (FGI)
CAC 40 (EURONEXT)
Biomea Fusion, Inc. (BMEA)
USD1.29
-0.01 (-0.39%)
US NASDAQ Healthcare Biotechnology
Address
900 Middlefield Road 94063
Redwood City, CA, US
Redwood City, CA, US
CEO
Michael J. Hitchcock
Website
biomeafusion.com
IPO
2021-04-16
CIK 1840439 ISIN US09077A1060
Description
Biomea Fusion, Inc. is a biopharmaceutical firm dedicated to discovering and developing innovative covalent small molecule therapies. These treatments are specifically designed for individuals suffering from genetically defined cancers and various metabolic ailments. The company's primary drug candidate, BMF-219, is a potent and selective covalent inhibitor of menin, engineered for oral administration. Menin plays a crucial role as a transcriptional regulator in the abnormal signaling pathways found across numerous cancer types. Established in 2017, Biomea Fusion's operations are headquartered in Redwood City, California.
Market Cap & Enterprise Value
Merger & Acquisition History
No mergers or acquisitions recorded for this company.
Technical Outlook
Loading outlook…
Loading forecast...
Signal Summary
Loading…
| Indicator | 1D | 1W | 2W | 3W | 1M |
|---|
Each column is computed on that timeframe's candles (1D = daily, 1W ≈ weekly, 1M ≈ monthly), not on the same last day. ▲ bullish · ▼ bearish · — neutral. The Net row counts signals per column; hover any cell (or the indicator name) to see the exact rule behind it.
Day Score & sub-scores
Statistical fingerprint & regime detail
Conditional historical analysis
Customize analysis (advanced)
Indicative levels generated algorithmically. Not financial advice.
Risk Profile
Loading risk profile…
Price Chart
USD1.29
-0.01 (-0.39%)
Loading historical data…
Volume Profile
Loading…
Liquidity & share structure
Average Volume
1M
Beta
-0.32
Float Shares
52.34M
Free Float %
88.0%
Price Performance
| 1D | 5D | 1M | 3M | 6M | YTD | 1Y | 3Y | 5Y | 10Y | Max |
|---|---|---|---|---|---|---|---|---|---|---|
| +0.64% | -1.25% | -15.51% | +26.40% | +15.33% | +27.42% | -10.73% | -95.35% | -90.05% | -90.71% | -90.71% |
Rolling Volatility
Loading…
Drawdown
Loading…
Relative Strength
Loading…
Monthly Returns Heatmap
From
To
Loading…
Annual Monthly Returns
Loading…
Daily Returns Distribution
Loading histogram data…
Revenue flow
Revenue by geography
Revenue by segment
From
To
Revenue composition
From
To
By product
By geography
Financial Statements
Select metrics from the tables below to build your comparison.
Income Statement
Balance Sheet
Cash Flow Statement
Key Metrics
Financial Ratios
Employees
Financial Growth (CAGR)
Market Data
Analyst Consensus (13 ratings, all time)
Buy
Price Targets & DCF
Current price
1.29
Low
10.00
+678.2%
Consensus
20.20
+1,472.0%
Median
19.00
+1,378.6%
High
40.00
+3,012.8%
DCF (Unlevered)
0.98
-23.8%
DCF (Levered)
1.04
-19.2%
DCF figures are point estimates: small changes in growth or discount-rate assumptions move them materially. Read them as a reference, not a precise target.
Ratings Trend (MoM)
88% Bullish
| Rating | 2026-05 | Change |
|---|---|---|
| Strong Buy | 2 | +1 |
| Buy | 5 | 0 |
| Hold | 0 | 0 |
| Sell | 0 | 0 |
| Strong Sell | 1 | 0 |
Price Target Summary
| Period | # Analysts | Avg Target |
|---|---|---|
| Last Month | — | — |
| Last Quarter | — | — |
| Last Year | — | — |
| All Time | 9 |
16.33
+1,170.8%
|
Quality scores
Altman Z-Score
-15.33
Distress
Piotroski F-Score
1 / 9
Weak
MOAT Score
3 / 10
No MOAT
Composite Rating
C
Overall Score
2 / 5
Medium
DCF Score
3 / 5
Medium
ROE Score
1 / 5
Low
ROA Score
1 / 5
Low
D/E Score
3 / 5
Medium
P/E Score
1 / 5
Low
P/Book Score
1 / 5
Low
Operational MOAT
✗ Below peers
-
Revenue growth Biotechnology: +1.6%—
-
EPS growth Biotechnology: +29.7%+69.2% ★ Q1'26: +78.8% (vs Q1'25)
-
FCF margin FCF growth · Biotechnology: +16.2%—
-
EBIT margin Biotechnology: +0.0%—
-
ROIC Biotechnology: -16.1%—
-
Share dilution Biotechnology: -3.4%+44.7% Q1'26: +97.4% (vs Q1'25)
-
Debt / EBITDA Net debt/EBITDA · Biotechnology: 0.16×-0.02× Q1'26: -0.02× (vs Q1'25)
Valuation Multiples
From
To
Consensus Estimates
| Metric |
Dec 2024 actual |
Dec 2025 actual |
Dec 2026 7 Rev. Ana. 5 EPS Ana. |
Dec 2027 8 Rev. Ana. 5 EPS Ana. |
Dec 2028 6 Rev. Ana. 5 EPS Ana. |
Dec 2029 5 Rev. Ana. 1 EPS Ana. |
Dec 2030 3 Rev. Ana. 1 EPS Ana. |
|---|---|---|---|---|---|---|---|
| Revenue |
—
est: 10.00M (-100.0%)
|
—
est: 2.50M (-100.0%)
|
3.00M
3.00M – 3.00M
+20.0% YoY
|
1.12M
1.12M – 1.12M
-62.8% YoY
|
4.13M
4.13M – 4.13M
+269.7% YoY
|
616.00M
616.00M – 616.00M
+14,816.1% YoY
|
107.05M
107.05M – 107.05M
-82.6% YoY
|
| EBITDA |
-142.32M
|
-79.90M
|
—
— – —
|
—
— – —
|
—
— – —
|
—
— – —
|
—
— – —
|
| EBIT |
-144.07M
|
-81.31M
|
—
— – —
|
—
— – —
|
—
— – —
|
—
— – —
|
—
— – —
|
| Net Income |
-138.43M
est: -199.16M (+30.5%)
|
-61.80M
est: -76.64M (+19.4%)
|
-70.68M
-72.87M – -31.47M
+7.8% YoY
|
-106.37M
-124.75M – -30.36M
-50.5% YoY
|
-72.94M
-108.90M – -36.98M
+31.4% YoY
|
-53.27M
-53.27M – -53.27M
+27.0% YoY
|
-4.18M
-4.18M – -4.18M
+92.2% YoY
|
| SGA |
25.99M
|
19.33M
|
—
— – —
|
—
— – —
|
—
— – —
|
—
— – —
|
—
— – —
|
| EPS |
-3.83
est: -3.89 (+1.5%)
|
-1.18
est: -1.53 (+23.0%)
|
-0.95
-1.40 – -0.60
+37.9% YoY
|
-1.19
-2.39 – -0.58
-25.1% YoY
|
-1.10
-2.09 – -0.71
+7.6% YoY
|
-1.02
-1.02 – -1.02
+7.2% YoY
|
-0.08
-0.08 – -0.08
+92.2% YoY
|
Recent Grade Changes (3M)
| Date | Firm | Previous | New Grade | Action |
|---|---|---|---|---|
| 2026-04-28 | D. Boral Capital | Buy | Buy | Maintain |
Historical Ratings (3M)
| Date | Rating | Overall | DCF | ROE | ROA | D/E | P/E | P/B |
|---|---|---|---|---|---|---|---|---|
| 2026-05-11 | C | 2/5 | 3/5 | 1/5 | 1/5 | 3/5 | 1/5 | 1/5 |
| 2026-05-08 | C | 2/5 | 3/5 | 1/5 | 1/5 | 3/5 | 1/5 | 2/5 |
| 2026-05-07 | C | 2/5 | 3/5 | 1/5 | 1/5 | 3/5 | 1/5 | 2/5 |
| 2026-05-06 | C | 2/5 | 3/5 | 1/5 | 1/5 | 3/5 | 1/5 | 2/5 |
| 2026-05-05 | C | 2/5 | 3/5 | 1/5 | 1/5 | 3/5 | 1/5 | 2/5 |
| 2026-05-04 | C | 2/5 | 3/5 | 1/5 | 1/5 | 3/5 | 1/5 | 2/5 |
| 2026-05-01 | C | 2/5 | 3/5 | 1/5 | 1/5 | 3/5 | 1/5 | 2/5 |
| 2026-04-30 | C | 2/5 | 3/5 | 1/5 | 1/5 | 3/5 | 1/5 | 2/5 |
| 2026-04-29 | C | 2/5 | 3/5 | 1/5 | 1/5 | 2/5 | 1/5 | 2/5 |
| 2026-04-28 | C | 2/5 | 3/5 | 1/5 | 1/5 | 2/5 | 1/5 | 2/5 |
| 2026-04-27 | C | 2/5 | 3/5 | 1/5 | 1/5 | 2/5 | 1/5 | 2/5 |
| 2026-04-24 | C | 2/5 | 3/5 | 1/5 | 1/5 | 2/5 | 1/5 | 2/5 |
| 2026-04-23 | C | 2/5 | 3/5 | 1/5 | 1/5 | 2/5 | 1/5 | 2/5 |
| 2026-04-22 | C | 2/5 | 3/5 | 1/5 | 1/5 | 2/5 | 1/5 | 2/5 |
| 2026-04-21 | C | 2/5 | 3/5 | 1/5 | 1/5 | 2/5 | 1/5 | 2/5 |
| 2026-04-20 | C | 2/5 | 3/5 | 1/5 | 1/5 | 2/5 | 1/5 | 2/5 |
| 2026-04-17 | C | 2/5 | 3/5 | 1/5 | 1/5 | 2/5 | 1/5 | 2/5 |
| 2026-04-16 | C | 2/5 | 3/5 | 1/5 | 1/5 | 2/5 | 1/5 | 2/5 |
Owner Earnings
Owner's Earnings (history)
Owner's Earnings history not available.
Owner alignment
Owner's Earnings TTM
—
OE per share TTM
—
Owner's Yield
—
Maintenance CapEx ratio
—
Maint CapEx / Avg PPE
—
Ownership Overview
Ownership breakdown
At a glance
Institutional holders
16
Total invested
9.60M
Insider transactions (90d)
0
Beneficial owners (>5%)
27
Beneficial owners (>5%)
| # | Reporting person | Amount owned | % of class | Sole voting | Shared voting | Sole dispositive | Shared dispositive | Type | Citizenship | Filing date | SEC filing |
|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | Thomas Butler | 5.37M | 18.30% | 528.0K | 4.85M | 528.0K | 4.85M | IN | — | 2022-02-11 | ↗ |
| 2 | Rainer M. Erdtmann | 4.99M | 17.10% | 141.6K | 4.85M | 141.6K | 4.85M | IN | — | 2022-02-11 | ↗ |
| 3 | STATE STREET CORPORATION | 4.49M | 12.50% | — | 4.41M | — | 4.49M | HC | BOSTON, MASSACHUSETTS | 2024-04-10 | ↗ |
| 4 | Point Sur Investors, LLC | 4.37M | 15.00% | 4.37M | — | 4.37M | — | PN | — | 2022-02-11 | ↗ |
| 5 | SSGA FUNDS MANAGEMENT, INC. | 4.04M | 11.25% | — | 4.03M | — | 4.04M | IA | BOSTON, MASSACHUSETTS | 2024-04-10 | ↗ |
| 6 | EIN #00-0000000 | 3.53M | 12.10% | — | 3.53M | — | 3.53M | IA, HC | Jersey, Channel Islands | 2022-02-10 | ↗ |
| 7 | Bihua Chen | 3.17M | 11.03% | 1.6K | 3.17M | 1.6K | 3.17M | IN | United States | 2021-04-30 | ↗ |
| 8 | Cormorant Asset Management, LP | 3.17M | 11.02% | — | 3.17M | — | 3.17M | PN | Delaware | 2021-04-30 | ↗ |
| 9 | Benjamin Alexander Smith | 2.74M | 7.66% | — | 2.74M | — | — | IN | Delaware | 2024-02-08 | ↗ |
| 10 | Janaka Sheehan Maduraperuma | 2.74M | 7.66% | — | 2.74M | — | — | IN | Delaware | 2024-02-08 | ↗ |
| 11 | Laurion Capital Management LP | 2.74M | 7.66% | — | 2.74M | — | — | IA, PN | Delaware | 2024-02-08 | ↗ |
| 12 | (1) BlackRock, Inc. | 2.16M | 6.00% | 2.13M | — | 2.16M | — | HC | Delaware | 2024-01-29 | ↗ |
| 13 | Baker Bros. Advisors (GP) LLC | 2.10M | 7.20% | 2.10M | — | 2.10M | — | HC, OO | Delaware | 2023-02-14 | ↗ |
| 14 | Baker Bros. Advisors LP | 2.10M | 7.20% | 2.10M | — | 2.10M | — | IA, PN | Delaware | 2023-02-14 | ↗ |
| 15 | Felix J. Baker | 2.10M | 7.20% | 2.10M | — | 2.10M | — | HC, IN | United States | 2023-02-14 | ↗ |
| 16 | Julian C. Baker | 2.10M | 7.20% | 2.10M | — | 2.10M | — | HC, IN | United States | 2023-02-14 | ↗ |
| 17 | Cormorant Private Healthcare Fund III, LP | 1.72M | 5.97% | — | 1.72M | — | 1.72M | PN | Delaware | 2021-04-30 | ↗ |
| 18 | Cormorant Private Healthcare GP III, LLC | 1.72M | 5.97% | — | 1.72M | — | 1.72M | OO | Delaware | 2021-04-30 | ↗ |
| 19 | (1)Names of reporting persons. BlackRock, Inc. | 1.67M | 5.80% | 1.67M | — | 1.67M | — | HC | Delaware | 2022-02-04 | ↗ |
| 20 | Cormorant Global Healthcare GP, LLC | 1.40M | 4.85% | — | 1.40M | — | 1.40M | OO | Delaware | 2021-04-30 | ↗ |
| 21 | Cormorant Global Healthcare Master Fund, LP | 1.40M | 4.85% | — | 1.40M | — | 1.40M | PN | Cayman Islands | 2021-04-30 | ↗ |
| 22 | Boxer Asset Management Inc. | 1.19M | 4.10% | — | 1.19M | — | 1.19M | CO | — | 2022-02-14 | ↗ |
| 23 | Boxer Capital, LLC | 1.19M | 4.10% | — | 1.19M | — | 1.19M | OO | — | 2022-02-14 | ↗ |
| 24 | Joe Lewis | 1.19M | 4.10% | — | 1.19M | — | 1.19M | IN | — | 2022-02-14 | ↗ |
| 25 | Point Sur Investors Fund I, L.P. | 480.8K | 1.70% | 480.8K | — | 480.8K | — | PN | — | 2022-02-11 | ↗ |
| 26 | Aaron I. Davis | 73.2K | 0.30% | — | 73.2K | — | 73.2K | OO | — | 2022-02-14 | ↗ |
| 27 | MVA Investors, LLC | 73.2K | 0.30% | — | 73.2K | — | 73.2K | OO | — | 2022-02-14 | ↗ |
Institutional Activity (13F)
Institutional ownership trend
From
To
13F snapshot — 2026 Q1
Investors holding
16
-50 vs prev Q
New positions
4
Closed positions
48
Increased
7
Reduced
2
Put/Call ratio
0.00
Calls held
—
Puts held
—
Top institutional holders
| # | Investor | Shares / Δ | Mkt value / Δ | Own% / Δ | Weight% / Δ | Avg px / Perf. | Hold / Status |
|---|---|---|---|---|---|---|---|
| 1 | FMR LLC | 8.81M +1.2M (+15.7%) | 10.93M -4.5M (-29.0%) | 21.69% +2.945 pp | 0.00% 0.000 pp | USD15.69 -92.1% | 19 qtrs — |
| 2 | VANGUARD GROUP INC | 2.97M +798.0K (+36.8%) | 3.68M -703.2K (-16.0%) | 7.31% +1.964 pp | 0.00% +0.000 pp | USD8.32 -85.1% | 19 qtrs — |
| 3 | AISLING CAPITAL MANAGEMENT LP | 2.05M +— (+0.0%) | 2.54M -1.6M (-38.6%) | 5.04% +0.000 pp | 0.53% -0.376 pp | USD7.18 -82.7% | 19 qtrs — |
| 4 | WOODLINE PARTNERS LP | 1.30M +— (+0.0%) | 1.61M -1.0M (-38.6%) | 3.20% +0.000 pp | 0.01% -0.006 pp | USD5.19 -76.1% | 12 qtrs — |
| 5 | MARSHALL WACE, LLP | 1.16M +865.6K (+293.7%) | 1.44M +843.5K (+141.7%) | 2.86% +2.131 pp | 0.00% +0.001 pp | USD1.65 -24.8% | 9 qtrs — |
| 6 | UBS GROUP AG | 785.3K +785.3K (+100.0%) | 973.8K +973.8K (+100.0%) | 1.93% +1.933 pp | 0.00% +0.000 pp | USD1.24 +0.0% | 1 qtrs NEW |
| 7 | BLACKROCK, INC. | 632.1K -269.5K (-29.9%) | 783.8K -1.0M (-57.0%) | 1.56% -0.663 pp | 0.00% +0.000 pp | USD8.77 -85.9% | 6 qtrs — |
| 8 | — | 631.5K +631.5K (+100.0%) | 783.0K +783.0K (+100.0%) | 1.55% +1.554 pp | 0.03% +0.028 pp | USD1.24 +0.0% | 1 qtrs NEW |
| 9 | MARINER, LLC | 585.6K +346.7K (+145.1%) | 726.2K +243.5K (+50.5%) | 1.44% +0.853 pp | 0.00% +0.000 pp | USD1.56 -20.5% | 2 qtrs — |
| 10 | GEODE CAPITAL MANAGEMENT, LLC | 562.9K +116.0K (+26.0%) | 698.1K -204.8K (-22.7%) | 1.39% +0.286 pp | 0.00% +0.000 pp | USD8.34 -85.1% | 19 qtrs — |
| 11 | RENAISSANCE TECHNOLOGIES LLC | 478.6K -117.3K (-19.7%) | 593.5K -610.2K (-50.7%) | 1.18% -0.289 pp | 0.00% -0.001 pp | USD2.02 -38.6% | 7 qtrs — |
| 12 | SUSQUEHANNA INTERNATIONAL GROUP, LLP | 478.0K +139.4K (+41.2%) | 592.8K -91.3K (-13.3%) | 1.18% +0.343 pp | 0.00% +0.000 pp | USD2.00 -38.0% | 14 qtrs — |
| 13 | TWO SIGMA INVESTMENTS, LP | 423.5K -139.5K (-24.8%) | 525.1K -612.1K (-53.8%) | 1.04% -0.343 pp | 0.00% -0.001 pp | USD3.66 -66.1% | 13 qtrs — |
| 14 | MORGAN STANLEY | 372.6K -70.4K (-15.9%) | 462.1K -432.9K (-48.4%) | 0.92% -0.173 pp | 0.00% +0.000 pp | USD11.40 -89.1% | 19 qtrs — |
| 15 | FEDERATED HERMES, INC. | 311.1K -260.9K (-45.6%) | 385.8K -769.8K (-66.6%) | 0.77% -0.642 pp | 0.00% -0.001 pp | USD2.48 -50.0% | 5 qtrs — |
| 16 | XTX TOPCO LTD | 261.1K -4.2K (-1.6%) | 323.7K -212.2K (-39.6%) | 0.64% -0.010 pp | 0.01% -0.019 pp | USD1.90 -34.7% | 7 qtrs — |
| 17 | SUPERSTRING CAPITAL MANAGEMENT LP | 250.0K +— (+0.0%) | 310.0K -195.0K (-38.6%) | 0.62% +0.000 pp | 0.17% -0.332 pp | USD1.80 -31.1% | 3 qtrs — |
| 18 | NORTHERN TRUST CORP | 209.0K +21.3K (+11.4%) | 259.1K -119.9K (-31.6%) | 0.51% +0.053 pp | 0.00% +0.000 pp | USD10.97 -88.7% | 19 qtrs — |
| 19 | STATE STREET CORP | 165.1K +25.0K (+17.8%) | 204.7K -78.3K (-27.7%) | 0.41% +0.062 pp | 0.00% +0.000 pp | USD10.69 -88.4% | 19 qtrs — |
| 20 | LMR PARTNERS LLP | 150.0K +150.0K (+100.0%) | 186.0K +186.0K (+100.0%) | 0.37% +0.369 pp | 0.00% +0.000 pp | USD1.24 +0.0% | 1 qtrs NEW |
| 21 | TWO SIGMA ADVISERS, LP | 105.8K -160.9K (-60.3%) | 131.2K -407.5K (-75.6%) | 0.26% -0.396 pp | 0.00% -0.001 pp | USD3.98 -68.8% | 10 qtrs — |
| 22 | MAREX GROUP PLC | 100.0K +— (+0.0%) | 124.0K -78.0K (-38.6%) | 0.25% +0.000 pp | 0.00% -0.001 pp | USD1.92 -35.4% | 3 qtrs — |
| 23 | SCULPTOR CAPITAL LP | 84.8K +— (+0.0%) | 105.2K -66.1K (-38.6%) | 0.21% +0.000 pp | 0.00% -0.001 pp | USD15.30 -91.9% | 8 qtrs — |
| 24 | QUADRATURE CAPITAL LTD | 69.9K -18.3K (-20.8%) | 86.7K -92.9K (-51.7%) | 0.17% -0.045 pp | 0.00% -0.001 pp | USD2.02 -38.6% | 4 qtrs — |
| 25 | JANE STREET GROUP, LLC | 69.5K -11.7K (-14.5%) | 86.2K -77.9K (-47.5%) | 0.17% -0.029 pp | 0.00% +0.000 pp | USD2.96 -58.1% | 12 qtrs — |
| 26 | GOLDMAN SACHS GROUP INC | 68.8K -197.2K (-74.1%) | 85.3K -452.1K (-84.1%) | 0.17% -0.485 pp | 0.00% 0.000 pp | USD7.60 -83.7% | 17 qtrs — |
| 27 | BRIDGEWAY CAPITAL MANAGEMENT, LLC | 68.3K -2.0K (-2.8%) | 84.7K -57.3K (-40.4%) | 0.17% -0.005 pp | 0.00% -0.001 pp | USD5.74 -78.4% | 6 qtrs — |
| 28 | BARCLAYS PLC | 59.0K +19.4K (+48.9%) | 73.2K -327.0K (-81.7%) | 0.15% +0.048 pp | 0.00% 0.000 pp | USD2.39 -48.1% | 16 qtrs — |
| 29 | GRIFFIN ASSET MANAGEMENT, INC. | 58.3K -3.0K (-4.9%) | 72.3K -51.5K (-41.6%) | 0.14% -0.007 pp | 0.01% -0.006 pp | USD10.26 -87.9% | 9 qtrs — |
| 30 | JAIN GLOBAL LLC | 55.2K +55.2K (+100.0%) | 68.4K +68.4K (+100.0%) | 0.14% +0.136 pp | 0.00% +0.000 pp | USD1.24 +0.0% | 3 qtrs — |
| 31 | ADAR1 CAPITAL MANAGEMENT, LLC | 43.4K +43.4K (+100.0%) | 53.8K +53.8K (+100.0%) | 0.11% +0.107 pp | 0.00% +0.004 pp | USD1.24 +0.0% | 1 qtrs NEW |
| 32 | CITIGROUP INC | 39.9K +38.7K (+3,312.5%) | 49.5K +47.1K (+1,994.2%) | 0.10% +0.095 pp | 0.00% +0.000 pp | USD1.48 -16.2% | 19 qtrs — |
| 33 | TWO SIGMA SECURITIES, LLC | 36.6K +36.6K (+100.0%) | 45.4K +45.4K (+100.0%) | 0.09% +0.090 pp | 0.01% +0.006 pp | USD1.24 +0.0% | 1 qtrs NEW |
| 34 | MILLENNIUM MANAGEMENT LLC | 25.7K +15.7K (+156.7%) | 31.8K +11.6K (+57.6%) | 0.06% +0.039 pp | 0.00% +0.000 pp | USD1.70 -27.1% | 17 qtrs — |
| 35 | DIMENSIONAL FUND ADVISORS LP | 25.3K +— (+0.0%) | 31.4K -19.8K (-38.7%) | 0.06% +0.000 pp | 0.00% +0.000 pp | USD10.41 -88.1% | 14 qtrs — |
| 36 | PNC FINANCIAL SERVICES GROUP, INC. | 24.0K +— (+0.0%) | 29.8K -18.7K (-38.6%) | 0.06% +0.000 pp | 0.00% +0.000 pp | USD7.70 -83.9% | 9 qtrs — |
| 37 | GSA CAPITAL PARTNERS LLP | 22.7K +22.7K (+100.0%) | 28.0K +28.0K (+100.0%) | 0.06% +0.056 pp | 0.00% +0.002 pp | USD1.24 +0.0% | 1 qtrs NEW |
| 38 | POINT72 ASSET MANAGEMENT, L.P. | 17.3K +17.3K (+100.0%) | 21.4K +21.4K (+100.0%) | 0.04% +0.043 pp | 0.00% +0.000 pp | USD1.24 +0.0% | 1 qtrs NEW |
| 39 | CREATIVE PLANNING | 12.0K -228.0 (-1.9%) | 14.9K -9.8K (-39.8%) | 0.03% -0.001 pp | 0.00% +0.000 pp | USD4.21 -70.5% | 7 qtrs — |
| 40 | CFS INVESTMENT ADVISORY SERVICES, LLC | 11.5K +— (+0.0%) | 14.2K -2.5K (-15.1%) | 0.03% +0.000 pp | 0.00% 0.000 pp | USD1.80 -31.1% | 3 qtrs — |
| 41 | ADVISOR GROUP HOLDINGS, INC. | 8.0K +843.0 (+11.8%) | 9.9K -4.5K (-31.1%) | 0.02% +0.002 pp | 0.00% +0.000 pp | USD6.07 -79.6% | 11 qtrs — |
| 42 | SBI SECURITIES CO., LTD. | 7.1K +1.0K (+16.5%) | 8.8K -3.5K (-28.5%) | 0.02% +0.003 pp | 0.00% 0.000 pp | USD2.22 -44.1% | 5 qtrs — |
| 43 | SIGNATUREFD, LLC | 3.5K +— (+0.0%) | 4.3K -2.8K (-39.1%) | 0.01% +0.000 pp | 0.00% +0.000 pp | USD11.48 -89.2% | 9 qtrs — |
| 44 | PINNACLE WEALTH PLANNING SERVICES, INC. | 3.3K +3.3K (+100.0%) | 4.1K +4.1K (+100.0%) | 0.01% +0.008 pp | 0.00% +0.000 pp | USD1.24 +0.0% | 1 qtrs NEW |
| 45 | JPMORGAN CHASE & CO | 3.3K +1.3K (+64.5%) | 4.1K +40.0 (+1.0%) | 0.01% +0.003 pp | 0.00% +0.000 pp | USD5.36 -76.9% | 19 qtrs — |
| 46 | QUEST PARTNERS LLC | 3.3K +— (+0.0%) | 4.1K -2.6K (-38.6%) | 0.01% +0.000 pp | 0.00% 0.000 pp | USD2.13 -41.8% | 9 qtrs — |
| 47 | ROCKEFELLER CAPITAL MANAGEMENT L.P. | 2.0K +— (+0.0%) | 2.5K -1.6K (-38.6%) | 0.00% +0.000 pp | 0.00% +0.000 pp | USD2.02 -38.6% | 2 qtrs — |
| 48 | BANK OF AMERICA CORP /DE/ | 1.3K -9.7K (-88.1%) | 1.6K -20.6K (-92.7%) | 0.00% -0.024 pp | 0.00% +0.000 pp | USD8.11 -84.7% | 19 qtrs — |
| 49 | RHUMBLINE ADVISERS | 1.2K +— (+0.0%) | 1.5K -936.0 (-38.6%) | 0.00% +0.000 pp | 0.00% +0.000 pp | USD16.11 -92.3% | 11 qtrs — |
| 50 | BNP PARIBAS ARBITRAGE, SNC | 1.1K -772.0 (-42.3%) | 1.3K -2.4K (-64.6%) | 0.00% -0.002 pp | 0.00% +0.000 pp | USD2.49 -50.2% | 5 qtrs — |
| 51 | FORTITUDE FAMILY OFFICE, LLC | 454.00 +158.0 (+53.4%) | 563.00 -35.0 (-5.9%) | 0.00% +0.000 pp | 0.00% +0.000 pp | USD1.74 -28.7% | 2 qtrs — |
| 52 | GLOBAL RETIREMENT PARTNERS, LLC | 375.00 +— (+0.0%) | 465.00 -293.0 (-38.7%) | 0.00% +0.000 pp | 0.00% +0.000 pp | USD1.80 -31.1% | 3 qtrs — |
| 53 | GLEN EAGLE ADVISORS, LLC | 250.00 +— (+0.0%) | 310.00 -195.0 (-38.6%) | 0.00% +0.000 pp | 0.00% +0.000 pp | USD14.52 -91.5% | 9 qtrs — |
| 54 | NATIONAL BANK OF CANADA /FI/ | 200.00 -123.4K (-99.8%) | 248.00 -249.4K (-99.9%) | 0.00% -0.304 pp | 0.00% 0.000 pp | USD1.80 -31.1% | 3 qtrs — |
| 55 | JONES FINANCIAL COMPANIES LLLP | 128.00 +53.0 (+70.7%) | 159.00 +1.0 (+0.6%) | 0.00% +0.000 pp | 0.00% +0.000 pp | USD2.78 -55.4% | 5 qtrs — |
| 56 | MAI CAPITAL MANAGEMENT | 100.00 +— (+0.0%) | 124.00 -78.0 (-38.6%) | 0.00% +0.000 pp | 0.00% +0.000 pp | USD2.02 -38.6% | 2 qtrs — |
| 57 | COMERICA BANK | 20.00 +— (+0.0%) | 25.00 -15.0 (-37.5%) | 0.00% +0.000 pp | 0.00% +0.000 pp | USD3.85 -67.8% | 5 qtrs — |
| 58 | WELLS FARGO & COMPANY/MN | 1.00 +— (+0.0%) | 1.00 -2.0 (-66.7%) | 0.00% +0.000 pp | 0.00% +0.000 pp | USD10.00 -87.6% | 17 qtrs — |
| 59 | MIRAE ASSET GLOBAL INVESTMENTS CO., LTD. | — -2.3K (-100.0%) | — -4.6K (-100.0%) | 0.00% -0.006 pp | 0.00% +0.000 pp | USD— | 11 qtrs SOLD |
| 60 | SQUAREPOINT OPS LLC | — -22.8K (-100.0%) | — -46.0K (-100.0%) | 0.00% -0.056 pp | 0.00% +0.000 pp | USD— | 10 qtrs SOLD |
| 61 | CORMORANT ASSET MANAGEMENT, LP | — -3.6M (-100.0%) | — -7.2M (-100.0%) | 0.00% -8.789 pp | 0.00% -0.498 pp | USD— | 19 qtrs SOLD |
| 62 | TOWER RESEARCH CAPITAL LLC (TRC) | — -7.2K (-100.0%) | — -14.5K (-100.0%) | 0.00% -0.018 pp | 0.00% 0.000 pp | USD— | 19 qtrs SOLD |
| 63 | CITADEL ADVISORS LLC | — -179.8K (-100.0%) | — -363.2K (-100.0%) | 0.00% -0.443 pp | 0.00% 0.000 pp | USD— | 19 qtrs SOLD |
| 64 | GROVE BANK & TRUST | — -2.9K (-100.0%) | — -5.8K (-100.0%) | 0.00% -0.007 pp | 0.00% -0.001 pp | USD— | 9 qtrs SOLD |
| 65 | CHINA UNIVERSAL ASSET MANAGEMENT CO., LTD. | — -10.4K (-100.0%) | — -21.1K (-100.0%) | 0.00% -0.026 pp | 0.00% -0.002 pp | USD— | 14 qtrs SOLD |
| 66 | VANGUARD PERSONALIZED INDEXING MANAGEMENT, LLC | — -16.0K (-100.0%) | — -32.4K (-100.0%) | 0.00% -0.040 pp | 0.00% 0.000 pp | USD— | 2 qtrs SOLD |
| 67 | VIRTU FINANCIAL LLC | — -19.1K (-100.0%) | — -39.0K (-100.0%) | 0.00% -0.047 pp | 0.00% -0.002 pp | USD— | 2 qtrs SOLD |
| 68 | PHYSICIAN WEALTH ADVISORS, INC. | — -1.2K (-100.0%) | — -2.4K (-100.0%) | 0.00% -0.003 pp | 0.00% 0.000 pp | USD— | 3 qtrs SOLD |
| 69 | HEIGHTS CAPITAL MANAGEMENT, INC | — -1.4M (-100.0%) | — -2.9M (-100.0%) | 0.00% -3.538 pp | 0.00% -0.796 pp | USD— | 3 qtrs SOLD |
| 70 | EVERSOURCE WEALTH ADVISORS, LLC | — -177.0 (-100.0%) | — -357.0 (-100.0%) | 0.00% 0.000 pp | 0.00% +0.000 pp | USD— | 5 qtrs SOLD |
| 71 | QUBE RESEARCH & TECHNOLOGIES LTD | — -10.0K (-100.0%) | — -20.3K (-100.0%) | 0.00% -0.025 pp | 0.00% +0.000 pp | USD— | 2 qtrs SOLD |
| 72 | NISA INVESTMENT ADVISORS, LLC | — -291.0 (-100.0%) | — -588.0 (-100.0%) | 0.00% -0.001 pp | 0.00% +0.000 pp | USD— | 11 qtrs SOLD |
| 73 | IFP ADVISORS, INC | — -54.0 (-100.0%) | — -109.0 (-100.0%) | 0.00% 0.000 pp | 0.00% +0.000 pp | USD— | 9 qtrs SOLD |
| 74 | ROYAL BANK OF CANADA | — -2.5K (-100.0%) | — -5.0K (-100.0%) | 0.00% -0.006 pp | 0.00% +0.000 pp | USD— | 19 qtrs SOLD |
| 75 | GF FUND MANAGEMENT CO. LTD. | — -1.3K (-100.0%) | — -2.6K (-100.0%) | 0.00% -0.003 pp | 0.00% +0.000 pp | USD— | 5 qtrs SOLD |
| 76 | SCIENTECH RESEARCH LLC | — -12.2K (-100.0%) | — -24.7K (-100.0%) | 0.00% -0.030 pp | 0.00% -0.009 pp | USD— | 2 qtrs SOLD |
| 77 | CWM, LLC | — -364.0 (-100.0%) | — -1.0K (-100.0%) | 0.00% -0.001 pp | 0.00% +0.000 pp | USD— | 6 qtrs SOLD |
Ownership breakdown by holder
ETF Ownership
Top ETFs holding this stock
Held by 12 ETFs in our universe
| # | ETF | Weight | Est. AUM exposure | TER |
|---|---|---|---|---|
| 1 | iShares Micro-Cap ETF IWC | 0.02% | 304.9K | 0.60% |
| 2 | Vanguard Extended Market ETF VXF | 0.00% | 855.4K | 0.05% |
| 3 | Vanguard U.S. Total Market Shares Index ETF VTS.AX | 0.00% | 6.2K | 0.03% |
| 4 | Vanguard U.S. Total Market Index ETF VUN.TO | 0.00% | 17.0K | 0.17% |
| 5 | Vanguard U.S. Total Market Index ETF (CAD-hedged) VUS.TO | 0.00% | 1.3K | 0.17% |
| 6 | Vanguard Total Stock Market ETF VTI | 0.00% | 2.91M | 0.03% |
| 7 | Vanguard All-Equity ETF Portfolio VEQT.TO | 0.00% | 6.4K | 0.22% |
| 8 | Vanguard Growth ETF Portfolio VGRO.TO | 0.00% | 3.5K | 0.22% |
| 9 | Vanguard Balanced ETF Portfolio VBAL.TO | 0.00% | 1.4K | 0.22% |
| 10 | Vanguard Conservative ETF Portfolio VCNS.TO | 0.00% | 154.69 | 0.22% |
Insider Activity
Insider Activity — Latest Quarter
Ratio by transactions
0.00
Bearish
Buys
2
Sells
0
Shares acquired
1.12M
Shares disposed
—
Cash buys
—
Cash sales
—
Net activity
+1,119,989
Insider buys vs sells (history)
From
To
Recent insider transactions
From
To
| Date | Person | Role | Transaction | A/D | Security | Shares | Price | Value | Owned after | D/I | Filing |
|---|---|---|---|---|---|---|---|---|---|---|---|
| 2026-04-01 | Hitchcock Michael J.M. | Director / Officer | A-Award | A | Stock Option (Right to Buy) | 667,477 | 1.49 | 994.5K | 667,477 | D | ↗ |
| 2026-04-01 | Erdtmann Rainer M | Director / Officer | A-Award | A | Stock Option (Right to Buy) | 452,512 | 1.49 | 674.2K | 452,512 | D | ↗ |
| 2025-12-31 | Erdtmann Rainer M | Director / Officer | — | — | Common Stock | 0 | 0.00 | — | 1,134,989 | I | ↗ |
| 2025-12-11 | Erdtmann Rainer M | Director / Officer | P-Purchase | A | Common Stock | 30,000 | 1.43 | 43.0K | 723,027 | D | ↗ |
| 2025-12-02 | Hitchcock Michael J.M. | Director / Officer | P-Purchase | A | Common Stock | 100,000 | 0.99 | 99.2K | 115,000 | D | ↗ |
| 2025-12-01 | Erdtmann Rainer M | Director / Officer | P-Purchase | A | Common Stock | 10,000 | 1.05 | 10.5K | 693,027 | D | ↗ |
| 2025-11-28 | Erdtmann Rainer M | Director / Officer | P-Purchase | A | Common Stock | 40,000 | 1.10 | 44.1K | 683,027 | D | ↗ |
| 2025-08-11 | Hitchcock Michael J.M. | Director / Officer | A-Award | A | Stock Option (Right to Buy) | 916,434 | 1.53 | 1.40M | 916,434 | D | ↗ |
| 2025-08-11 | Erdtmann Rainer M | Director / Officer | A-Award | A | Stock Option (Right to Buy) | 1,246,989 | 1.53 | 1.91M | 1,246,989 | D | ↗ |
| 2025-08-01 | Chen Bihua | — | — | — | — | 0 | 0.00 | — | 0 | — | ↗ |
| 2025-07-22 | Averill Julianne | Director | A-Award | A | Stock Option (Right to Buy) | 241,177 | 1.82 | 438.9K | 241,177 | D | ↗ |
| 2025-06-11 | Ray Sumita | Director | A-Award | A | Stock Option (Right to Buy) | 91,970 | 2.50 | 229.9K | 91,970 | D | ↗ |
| 2025-06-11 | Faust Elizabeth | Director | A-Award | A | Stock Option (Right to Buy) | 91,970 | 2.50 | 229.9K | 91,970 | D | ↗ |
| 2025-06-11 | Chen Bihua | Director / 10% Owner | A-Award | A | Stock Option (Right to Buy) | 91,970 | 2.50 | 229.9K | 91,970 | D | ↗ |
| 2025-06-11 | AGUIAR ERIC | Director | A-Award | A | Stock Option (Right to Buy) | 91,970 | 2.50 | 229.9K | 91,970 | D | ↗ |
| 2025-03-26 | Hitchcock Michael J.M. | Director / Officer | A-Award | A | Stock Option (Right to Buy) | 350,000 | 2.52 | 882.0K | 350,000 | D | ↗ |
| 2025-01-31 | Erdtmann Rainer M | Director / Officer | G-Gift | A | Common Stock | 10,000 | 0.00 | — | 20,000 | I | ↗ |
| 2025-01-28 | Erdtmann Rainer M | Director / Officer | G-Gift | D | Common Stock | 40,000 | 0.00 | — | 673,027 | D | ↗ |
| 2024-11-30 | Valle Franco | Officer | A-Award | A | Common Stock | 495 | 6.15 | 3.0K | 42,995 | D | ↗ |
| 2024-09-30 | Hitchcock Michael J.M. | Director | P-Purchase | A | Common Stock | 10,000 | 10.06 | 100.6K | 15,000 | D | ↗ |
| 2024-06-12 | Ray Sumita | Director | A-Award | A | Stock Option (Right to Buy) | 51,025 | 4.63 | 236.2K | 51,025 | — | ↗ |
| 2024-06-12 | Hitchcock Michael J.M. | Director | A-Award | A | Stock Option (Right to Buy) | 51,025 | 4.63 | 236.2K | 51,025 | — | ↗ |
| 2024-06-12 | Faust Elizabeth | Director | A-Award | A | Stock Option (Right to Buy) | 51,025 | 4.63 | 236.2K | 51,025 | — | ↗ |
| 2024-06-12 | Chen Bihua | Director / 10% Owner | A-Award | A | Stock Option (right to buy) | 51,025 | 4.63 | 236.2K | 51 | — | ↗ |
| 2024-06-12 | AGUIAR ERIC | Director | A-Award | A | Stock Option (Right to Buy) | 51,025 | 4.63 | 236.2K | 51,025 | — | ↗ |
| 2024-06-11 | Valle Franco | Officer | P-Purchase | A | Common Stock | 12,509 | 4.43 | 55.4K | 42,500 | — | ↗ |
| 2024-05-31 | Valle Franco | Officer | A-Award | A | Common Stock | 4,448 | 3.78 | 16.8K | 29,991 | — | ↗ |
| 2024-05-31 | Frias Juan Pablo | Officer | A-Award | A | Common Stock | 349 | 8.94 | 3.1K | 349 | — | ↗ |
| 2024-01-17 | Valle Franco | Officer | A-Award | A | Stock Option (Right to Buy) | 145,245 | 14.44 | 2.10M | 145,245 | — | ↗ |
| 2024-01-17 | Frias Juan Pablo | Officer | A-Award | A | Stock Option (Right to Buy) | 111,090 | 14.44 | 1.60M | 111,090 | — | ↗ |
| 2024-01-17 | Erdtmann Rainer M | Director / Officer | A-Award | A | Stock Option (Right to Buy) | 135,700 | 14.44 | 1.96M | 135,700 | — | ↗ |
| 2024-01-17 | Butler Thomas Andrew | Director / Officer / 10% Owner | A-Award | A | Stock Option (Right to Buy) | 407,502 | 14.44 | 5.88M | 407,502 | — | ↗ |
| 2023-12-29 | Erdtmann Rainer M | Director / Officer | G-Gift | D | Common Stock | 3,000 | 0.00 | — | 725,027 | — | ↗ |
| 2023-11-30 | Valle Franco | Officer | A-Award | A | Common Stock | 1,345 | 3.78 | 5.1K | 25,543 | — | ↗ |
| 2023-08-31 | Frias Juan Pablo | Officer | A-Award | A | Stock Option (Right to Buy) | 300,000 | 16.87 | 5.06M | 300,000 | — | ↗ |
| 2023-06-14 | Ray Sumita | Director | A-Award | A | Stock Option (Right to Buy) | 6,989 | 38.90 | 271.9K | 6,989 | — | ↗ |
| 2023-06-14 | Hitchcock Michael J.M. | Director | A-Award | A | Stock Option (Right to Buy) | 6,989 | 38.90 | 271.9K | 6,989 | — | ↗ |
| 2023-06-14 | Faust Elizabeth | Director | A-Award | A | Stock Option (Right to Buy) | 6,989 | 38.90 | 271.9K | 6,989 | — | ↗ |
| 2023-06-14 | Chen Bihua | Director / 10% Owner | A-Award | A | Stock Option (right to buy) | 6,989 | 38.90 | 271.9K | 6,989 | — | ↗ |
| 2023-06-14 | AGUIAR ERIC | Director | A-Award | A | Stock Option (Right to Buy) | 6,989 | 38.90 | 271.9K | 6,989 | — | ↗ |
| 2023-06-01 | A2A Pharmaceuticals, Inc. | 10% Owner | S-Sale | D | Common Stock | 50,000 | 34.56 | 1.73M | 3,500,000 | — | ↗ |
| 2023-05-31 | Valle Franco | Officer | A-Award | A | Common Stock | 4,273 | 3.78 | 16.2K | 24,198 | — | ↗ |
| 2023-05-31 | A2A Pharmaceuticals, Inc. | 10% Owner | S-Sale | D | Common Stock | 75,000 | 33.81 | 2.54M | 3,550,000 | — | ↗ |
| 2023-05-12 | A2A Pharmaceuticals, Inc. | 10% Owner | S-Sale | D | Common Stock | 25,000 | 33.84 | 846.0K | 3,625,000 | — | ↗ |
| 2023-05-09 | A2A Pharmaceuticals, Inc. | 10% Owner | S-Sale | D | Common Stock | 150,000 | 34.50 | 5.18M | 3,650,000 | — | ↗ |
| 2023-05-08 | A2A Pharmaceuticals, Inc. | 10% Owner | S-Sale | D | Common Stock | 100,000 | 33.99 | 3.40M | 3,800,000 | — | ↗ |
| 2023-04-20 | A2A Pharmaceuticals, Inc. | 10% Owner | S-Sale | D | Common Stock | 200,000 | 29.12 | 5.82M | 3,900,000 | — | ↗ |
| 2023-03-31 | A2A Pharmaceuticals, Inc. | 10% Owner | S-Sale | D | Common Stock | 200,000 | 31.25 | 6.25M | 4,100,000 | — | ↗ |
| 2023-03-30 | Chen Bihua | Director / 10% Owner | P-Purchase | A | Common Stock | 400,000 | 30.00 | 12.00M | 3,570,872 | — | ↗ |
| 2023-01-06 | Valle Franco | Officer | A-Award | A | Stock Option (Right to Buy) | 126,300 | 0.00 | — | 126,300 | — | ↗ |
| 2023-01-06 | Erdtmann Rainer M | Officer | A-Award | A | Stock Option (Right to Buy) | 118,000 | 0.00 | — | 118,000 | — | ↗ |
| 2023-01-06 | Butler Thomas Andrew | Officer | A-Award | A | Stock Option (Right to Buy) | 354,350 | 0.00 | — | 354,350 | — | ↗ |
| 2022-12-31 | Erdtmann Rainer M | Director / Officer | — | I | Common Stock | 0 | 0.00 | — | 174,614 | — | ↗ |
| 2022-11-30 | Valle Franco | Officer | A-Award | A | Common Stock | 2,518 | 3.78 | 9.5K | 19,925 | — | ↗ |
| 2022-11-14 | Hitchcock Michael J.M. | Director | P-Purchase | A | Common Stock | 5,000 | 7.93 | 39.7K | 5,000 | — | ↗ |
| 2022-11-11 | Valle Franco | Officer | P-Purchase | A | Common Stock | 4,100 | 7.63 | 31.3K | 17,407 | — | ↗ |
| 2022-08-16 | A2A Pharmaceuticals, Inc. | Director | P-Purchase | D | Common Stock | 30,684 | 13.87 | 425.6K | 4,300,000 | — | ↗ |
| 2022-07-21 | A2A Pharmaceuticals, Inc. | Director | S-Sale | D | Common Stock | 34,658 | 11.21 | 388.5K | 4,330,684 | — | ↗ |
| 2022-06-24 | A2A Pharmaceuticals, Inc. | Director | S-Sale | D | Common Stock | 34,658 | 11.76 | 407.6K | 4,365,342 | — | ↗ |
| 2022-06-22 | Ray Sumita | Director | A-Award | A | Stock Option (Right to Buy) | 23,867 | 10.20 | 243.4K | 23,867 | — | ↗ |
| 2022-06-22 | Hitchcock Michael J.M. | Director | A-Award | A | Stock Option (Right to Buy) | 23,867 | 0.00 | — | 23,867 | — | ↗ |
| 2022-06-22 | Faust Elizabeth | Director | — | — | — | 0 | 0.00 | — | 0 | — | ↗ |
| 2022-06-22 | Cormorant Asset Management, LP | Director | A-Award | A | Stock Option (right to buy) | 23,867 | 0.00 | — | 23,867 | — | ↗ |
| 2022-06-22 | Chen Bihua | Director / 10% Owner | A-Award | A | Stock Option (right to buy) | 23,867 | 10.20 | 243.4K | 23,867 | — | ↗ |
| 2022-06-22 | AGUIAR ERIC | Director | A-Award | A | Stock Option (Right to Buy) | 23,867 | 10.20 | 243.4K | 23,867 | — | ↗ |
| 2022-06-01 | Biomea Health, LLC | Director | J-Other | D | Common Stock | 4,365,342 | 0.00 | — | 0 | — | ↗ |
| 2022-05-31 | Valle Franco | Officer | A-Award | A | Common Stock | 3,307 | 4.67 | 15.4K | 13,307 | — | ↗ |
| 2022-03-03 | Ray Sumita | Director | A-Award | A | Stock Option (Right to Buy) | 21,461 | 0.00 | — | 21,461 | — | ↗ |
| 2022-01-14 | Valle Franco | Officer | P-Purchase | A | Common Stock | 10,000 | 8.68 | 86.8K | 10,000 | — | ↗ |
| 2021-12-04 | Valle Franco | Officer | A-Award | A | Stock Option (Right to Buy) | 144,770 | 9.80 | 1.42M | 144,770 | — | ↗ |
| 2021-12-04 | Erdtmann Rainer M | Director / Officer / 10% Owner | A-Award | A | Stock Option (Right to Buy) | 165,490 | 9.80 | 1.62M | 165,490 | — | ↗ |
| 2021-12-04 | Butler Thomas Andrew | Director / Officer / 10% Owner | A-Award | A | Stock Option (Right to Buy) | 305,400 | 9.80 | 2.99M | 305,400 | — | ↗ |
| 2021-09-17 | Stergiopoulos Sotirios | Director | P-Purchase | A | Common Stock | 34,658 | 10.96 | 379.9K | 4,400,000 | — | ↗ |
| 2021-09-17 | A2A Pharmaceuticals, Inc. | 10% Owner | P-Purchase | A | Common Stock | 34,658 | 10.96 | 379.9K | 4,400,000 | — | ↗ |
| 2021-08-23 | Erdtmann Rainer M | Director / Officer / 10% Owner | P-Purchase | A | Common Stock | 24,000 | 13.20 | 316.9K | 228,470 | — | ↗ |
| 2021-08-23 | Butler Thomas Andrew | Director / Officer / 10% Owner | P-Purchase | A | Common Stock | 24,000 | 13.20 | 316.9K | 228,470 | — | ↗ |
| 2021-08-18 | Erdtmann Rainer M | Director / Officer / 10% Owner | P-Purchase | A | Common Stock | 14,000 | 10.77 | 150.7K | 204,470 | — | ↗ |
| 2021-08-18 | Butler Thomas Andrew | Director / Officer / 10% Owner | P-Purchase | A | Common Stock | 14,000 | 10.77 | 150.7K | 204,470 | — | ↗ |
| 2021-08-17 | Erdtmann Rainer M | Officer | P-Purchase | A | Common Stock | 14,000 | 10.79 | 151.1K | 190,470 | — | ↗ |
| 2021-08-17 | Butler Thomas Andrew | Director / Officer / 10% Owner | P-Purchase | A | Common Stock | 14,000 | 10.79 | 151.1K | 190,470 | — | ↗ |
| 2021-08-03 | Valle Franco | Officer | A-Award | A | Stock Option (Right to Buy) | 165,000 | 13.45 | 2.22M | 165,000 | — | ↗ |
| 2021-07-26 | Valle Franco | Officer | — | — | — | 0 | 0.00 | — | 0 | — | ↗ |
| 2021-06-16 | Ray Sumita | Director | A-Award | A | Stock Option (Right to Buy) | 17,724 | 20.46 | 362.6K | 17,724 | — | ↗ |
| 2021-04-20 | Chen Bihua | Director | P-Purchase | A | Common Stock | 900,000 | 17.00 | 15.30M | 3,170,872 | — | ↗ |
| 2021-04-15 | Stergiopoulos Sotirios | Director | A-Award | A | Stock Option (Right to Buy) | 28,911 | 17.00 | 491.5K | 28,911 | — | ↗ |
| 2021-04-15 | Ryan Sunny | Officer | — | D | Common Stock | 0 | 0.00 | — | 63,114 | — | ↗ |
| 2021-04-15 | Hitchcock Michael J.M. | Director | — | — | — | 0 | 0.00 | — | 0 | — | ↗ |
| 2021-04-15 | Erdtmann Rainer M | Director / Officer / 10% Owner | P-Purchase | A | Common Stock | 3,000 | 17.00 | 51.0K | 3,000 | — | ↗ |
| 2021-04-15 | Cormorant Asset Management, LP | Director / 10% Owner | A-Award | D | Stock Option (right to buy) | 28,911 | 17.00 | 491.5K | 28,911 | — | ↗ |
| 2021-04-15 | Chen Bihua | Director / 10% Owner | — | I | Series A Convertible Preferred Stock | 2,270,872 | 0.00 | — | 0 | — | ↗ |
| 2021-04-15 | Butler Thomas Andrew | Director / Officer / 10% Owner | — | I | Common Stock | 0 | 0.00 | — | 2,182,671 | — | ↗ |
| 2021-04-15 | Biomea Health, LLC | 10% Owner | — | I | Common Stock | 0 | 0.00 | — | 4,365,342 | — | ↗ |
| 2021-04-15 | AGUIAR ERIC | Director | — | — | — | 0 | 0.00 | — | 0 | — | ↗ |
| 2021-04-15 | A2A Pharmaceuticals, Inc. | 10% Owner | — | D | Common Stock | 0 | 0.00 | — | 4,365,342 | — | ↗ |
Executive team
Top executives
Shares Outstanding
59.50M
Executive compensation
Executive compensation (annual)
| # | Year | Executive | Salary | Bonus | Stock award | Option award | Incentive | Other | Total | % Stock- based |
Filing |
|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | 2025 | Michael J.M. Hitchcock, Ph.D. Interim Chief Executive Officer and Principal Executive Officer | 486.7K | 220.1K | — | 1.85M | — | 14.1K | 2.57M | 71.94% | ↗ |
| 2 | 2025 | Rainer (Ramses) Erdtmann Chief Operating Officer, President, Principal Financial Officer and Principal Accounting Officer | 489.6K | 146.9K | — | 1.57M | — | — | 2.21M | 71.21% | ↗ |
| 3 | 2025 | Thomas Butler Former Chief Executive Officer and Former Chairman of the Board | 148.8K | — | — | — | — | 513.2K | 662.0K | 0.00% | ↗ |
| 4 | 2025 | Juan Pablo Frias, M.D. Former Chief Medical Officer | 325.0K | — | — | 158.7K | — | 65.3K | 549.0K | 28.91% | ↗ |
| 5 | 2024 | Thomas Butler Former Chief Executive Officer and Former Chairman of the Board | 633.6K | — | — | 4.47M | — | — | 5.11M | 87.59% | ↗ |
| 6 | 2024 | Franco Valle Former Chief Financial Officer | 483.8K | — | — | 1.59M | — | — | 2.08M | 76.72% | ↗ |
| 7 | 2024 | Rainer (Ramses) Erdtmann Chief Operating Officer and President | 489.6K | — | — | 1.49M | — | — | 1.98M | 75.26% | ↗ |
| 8 | 2024 | Rainer (Ramses) Erdtmann Chief Operating Officer, President, Principal Financial Officer and Principal Accounting Officer | 489.6K | — | — | 1.49M | — | — | 1.98M | 75.26% | ↗ |
| 9 | 2023 | Juan Pablo Frias, M.D. Chief Medical Officer | 168.4K | 75.5K | — | 3.68M | — | 12.6K | 3.93M | 93.48% | ↗ |
| 10 | 2023 | Thomas Butler Former Chief Executive Officer and Former Chairman of the Board | 609.2K | 341.2K | — | 1.76M | — | — | 2.71M | 64.89% | ↗ |
| 11 | 2023 | Thomas Butler Chief Executive Officer and Chairman of the Board | 609.2K | 341.2K | — | 1.76M | — | — | 2.71M | 64.89% | ↗ |
| 12 | 2023 | Franco Valle Chief Financial Officer | 465.2K | 208.4K | — | 626.2K | — | — | 1.30M | 48.17% | ↗ |
| 13 | 2023 | Franco Valle Former Chief Financial Officer | 465.2K | 208.4K | — | 626.2K | — | — | 1.30M | 48.17% | ↗ |
| 14 | 2023 | Rainer (Ramses) Erdtmann Chief Operating Officer and President | 470.8K | 210.9K | — | 585.1K | — | — | 1.27M | 46.19% | ↗ |
| 15 | 2022 | Thomas Butler Chief Executive Officer and Chairman of the Board | 583.0K | 338.1K | — | — | — | — | 921.1K | 0.00% | ↗ |
| 16 | 2022 | Rainer (Ramses) Erdtmann Chief Operating Officer and President | 450.5K | 209.0K | — | — | — | — | 659.5K | 0.00% | ↗ |
| 17 | 2022 | Franco Valle Chief Financial Officer | 445.2K | 206.6K | — | — | — | — | 651.8K | 0.00% | ↗ |
| 18 | 2021 | Thomas Butler Chief Executive Officer and Chairman of the Board | 552.0K | 220.8K | — | 5.89M | — | — | 6.66M | 88.40% | ↗ |
| 19 | 2021 | Thomas Butler Chief Executive Officer and Chairman of the Board | 552.0K | 220.8K | — | 5.89M | — | — | 6.66M | 88.40% | ↗ |
| 20 | 2021 | Franco Valle Chief Financial Officer | 185.8K | 65.9K | — | 2.71M | — | — | 2.96M | 91.49% | ↗ |
| 21 | 2021 | Rainer (Ramses) Erdtmann Chief Operating Officer and President | 429.5K | 141.1K | — | 2.33M | — | — | 2.90M | 80.33% | ↗ |
| 22 | 2021 | Ramses Erdtmann Chief Operating Officer and President | 429.5K | 141.1K | — | 2.33M | — | — | 2.90M | 80.33% | ↗ |
| 23 | 2020 | Thomas Butler Chief Executive Officer and Chairman of the Board | 228.8K | 134.4K | 1.15M | — | — | — | 1.52M | 76.05% | ↗ |
| 24 | 2020 | Ramses Erdtmann Chief Operating Officer and President | 14.8K | 21.4K | 270.7K | — | — | — | 306.9K | 88.21% | ↗ |
CEO compensation breakdown
Proxy statements
Proxy statements (DEF 14A)
Recent SEC filings
Executive team
| Name | Title | Compensation | Gender |
|---|---|---|---|
| Michael J. Hitchcock | Interim Chief Executive Officer & Director | 867.9K | — |
| Ramses Erdtmann | Co-Founder, President, Chief Operating Officer & Director | 636.5K | male |
| Heow Tan | Chief Technology & Quality Officer | — | male |
| Caroline Perez- Dupont | Senior Vice President of Contracts | — | — |
| Ravi Upasani | Executive Vice President of Intellectual Property | — | male |
| Stephan Morris | Chief Development Officer | — | — |
| Thorsten Kirschberg | Executive Vice President of Research | — | — |
ESG Rating
ESG Score History BIOTECHNOLOGY
Benchmark vs Sector
Senate Trading Activity
No Senate trading activity found for this company.
House Trading Activity
No House trading activity found for this company.
Market share among peers
Peer comparison — filtered group (TTM)
Your opinion
Share your view on this stock and instantly see how the community has voted over the last 6 months.
Community Opinion for BMEA
Short-term intention
Target Price Distribution
These are community opinions and do not constitute buy or sell advice to act on. The results shown are based on aggregated opinions and are not an investment recommendation, nor do they intend to influence any investment decision.
